Testosterone gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, which include congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism.

Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. OAB is characterized by a sudden urge to urinate that is difficult to control.

Brendan O’Grady, Executive Vice President and Head of North America Commercial at Teva says, ‘About 33 million Americans have overactive bladder. We’re proud to offer another treatment option for this common condition’.

According to IQVIA data from February 2019, testosterone gel 1.62% CIII has annual sales of over US$911 million; and VESIcare tablets have annual sales of over US$955 million, in the US.

Related article
Teva launches generic testosterone

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.